-

Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that it will release second quarter 2020 results after the market close on Monday, August 10, 2020 and host a conference call at 4:30 p.m. ET to discuss second quarter 2020 results as well as to provide a general business update.

Dial-in Number

U.S. Dial-In: 877-300-8521
Int’l Dial-In: 412-317-6026

Passcode: 10147071

Webcast
http://public.viavid.com/index.php?id=141126

A live webcast of the call will also be available online in the investor relations section of Forte’s website at https://www.fortebiorx.com/ and will be archived there until August 17, 2020.

About Forte

Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. Forte plans to advance FB-401 into a randomized Phase 2 clinical trial in mid-2020.

Source: Forte Biosciences, Inc.

Contacts

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

Industry:

Forte Biosciences, Inc.

NASDAQ:FBRX
Release Versions
English

Contacts

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

More News From Forte Biosciences, Inc.

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will...

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s B...

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s B...
Back to Newsroom